Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 502 Results

Page 27 of 51« First «...10 20...25 262728 29...40 50...»Last »

September 5, 2018

DBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the European Congress of Immunology

August 31, 2018

DBV Technologies to Attend Upcoming Investor Conferences

July 27, 2018

DBV Technologies Reports June 30, 2018 Cash Position

July 27, 2018

DBV Technologies Reports June 30, 2018 Cash Position

July 26, 2018

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

July 13, 2018

Half-Year Report on the DBV Technologies Liquidity Contract and Transfer to Oddo BHF

June 22, 2018

DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel

June 5, 2018

DBV Technologies to Attend Upcoming Investor Conferences

June 1, 2018

Annual General Meeting, June 22, 2018

May 29, 2018

Annual General Meeting, June 22, 2018

Page 27 of 51« First «...10 20...25 262728 29...40 50...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Cookies Policy

Scroll to Top